BioSpace News Archive

Microbix Biosystems Inc. announces the issuance of stock options under its shareholder-approved 2018 stock option plan (the “Stock Option Plan”), as part of its compensation programs to incentivize and retain its board of directors, executives, and managers.

Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced it has reached an agreement with the New Therapies (NT) Council which will result in reimbursed access to Libmeldy ® (atidarsagene autotemcel) for all metachromatic leukodystrophy (MLD) patients who fall within the scope of the European marketing authorization in Sweden.

Amarin Corporation plc (NASDAQ:AMRN) today announced that data evaluating the role of VASCEPA®/VAZKEPA® (icosapent ethyl) and eicosapentaenoic acid (EPA) in reducing cardiovascular events in at-risk patients will be presented at the joint ACC.23 together with the World Congress of Cardiology (ACC.23/WCC) in New Orleans, LA, March 4-6, 2023.

Immuneering Corporation announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2022 on Monday, March 6 after the close of trading.

Cullinan Oncology, Inc. today announced that its President and Chief Executive Officer, Nadim Ahmed, will present at Cowen’s 43rd Annual Health Care Conference on March 6, 2023 at 11:10 AM EST.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the publication of results from the global, multi-center, open-label, Phase 3 clinical trial (MT-1186-A01) evaluating the long-term safety and tolerability of RADICAVA ORS® (edaravone) in the treatment of amyotrophic lateral sclerosis (ALS) over 48 weeks of treatment.

Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced positive results from the company’s Phase 1 clinical trial of MZE001 in healthy volunteers.

At SLAS 2023, SCIEX, a global leader in life science analytical technologies, announces a new collaboration with Beckman Coulter Life Sciences, a global leader in laboratory workflow automation and innovation, to provide comprehensive workflows for high-throughput screening, HT-ADME and synthetic biology studies.

Lucy Scientific Discovery Inc. (“Lucy” or the “Company”) [NASDAQ:LSDI] announced today that it has agreed to its first commercial sale to the prestigious Hadassah BrainLabs - Center for Psychedelics Research, Hadassah Medical Center, Hebrew University, Jerusalem, Israel.

VisionHealth raises 3 million Euro to finance extended COPD and asthma study for market preparation of Kata®, an innovative digital therapeutic for improved inhalation